VBI Publishes on Phase 3 3-Antigen Hepatitis B Vaccine Study

 

• Publication title: "Immunogenicity and safety of a 3-Antigen Hepatitis B Vaccine vs a Single-Antigen Hepatitis B Vaccine; A Phase 3 Randomized Clinical Trial"

• The Phase 3 study, in 2,838 adults age 18-45, evaluated immunogenicity, safety, and lot-to-lot manufacturing equivalence of VBI’s 3-antigen hepatitis B vaccine candidate compared to Engerix-B®

• VBI’s vaccine candidate demonstrated robust and consistent immune responses across all three lots after two and three doses, with higher seroprotection rates and antibody geometric mean concentration (GMC) compared to Engerix-B®

• No safety signals were observed

https://finance.yahoo.com/news/vbi-vaccines-announces-publication-results-120000936.html